A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
In brief
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD).
Key facts
- Study ID
- NCT06024239
- Run by
- AbbVie
- People needed
- 72
- Starts
- 2023-08-31
- Expected to finish
- 2025-03-04
- Last updated by the study team
- 2025-03-17
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- For healthy volunteer cohort:
- - Body mass index (BMI) is >= 18.0 to <= 32.0 kg/m2 after rounding to the tenths decimal.
- For participants with generalized anxiety disorder (GAD) or bipolar disorder (BPD)
- Participants with GAD or BPD (as confirmed by MINI) meet participant psychiatric history criteria described in the protocol.
You may not qualify if…
- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
Where it is running
- Collaborative Neuroscience Research CNS /ID# 260270 — Los Alamitos, California, United States
- Acpru /Id# 255945 — Grayslake, Illinois, United States
- Hassman Research Institute Marlton Site /ID# 260271 — Marlton, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.